Geneva (Agencies) July 13, 2025 — Global biotech researchers are accelerating efforts to develop plant-based edible vaccines, a revolutionary approach that could transform immunization by embedding vaccine proteins directly into common foods like bananas, tomatoes, lettuce, and potatoes. These genetically modified crops are designed to produce antigens—proteins that trigger immune responses—allowing people to gain protection against diseases simply by eating them.
The concept, known as molecular pharming, uses advanced genetic engineering to insert antigen-producing genes into plant cells. Once grown, these plants express vaccine proteins in their edible tissues, offering a needle-free, cost-effective, and room-temperature-stable alternative to traditional vaccines.
Key disease targets include:
- Hepatitis B and C
- Cholera and diarrheal diseases
- Respiratory infections like RSV and influenza
- Emerging threats such as SARS-CoV-2 variants and dengue
Bananas and tomatoes are particularly promising due to their palatability and ability to preserve antigen integrity. For instance, transgenic bananas have successfully expressed hepatitis B and cholera antigens, while tomatoes have shown efficacy in delivering norovirus and RSV vaccines.
However, the technology remains in early-stage trials, with no edible vaccines yet approved for public use. Researchers are working to overcome challenges such as dosage consistency, antigen stability during digestion, and public acceptance of genetically modified foods. To prevent accidental mixing with the food supply, these crops are grown in controlled greenhouse environments, separate from conventional agriculture.
Critics have raised ethical concerns about transparency, warning that if edible vaccines were introduced into the food supply without clear labeling or public awareness, it could erode trust and violate informed consent principles. Regulatory bodies like the FDA and WHO have emphasized that any edible vaccine must meet rigorous standards for safety, efficacy, and traceability.
Despite these hurdles, biotech firms such as Aramis Biotechnologies and academic institutions in Canada, India, and the U.S. are pushing forward, citing the potential to democratize vaccine access in low-resource settings and respond rapidly to pandemics.